News

Who Owns your House? And Why Does It Matter? By Kevin Owens

Lately, the “American Dream” is starting to look a bit different than it did for previous generations. The colloquial saying refers to a utopic idea, which often includes homeownership, a goal shared not only by young people in the United States, where the phrase is commonly quoted, but around the world. Many factors affect house…
Read More

New ‘Premium Economy’ Class On Flights by Aminah Ayub

The price difference between economy and business class seats on flights is staggering. Ticket prices vary depending on route and demand, but, on United Airlines, a seat in economy class (for a long haul flight) can cost you $1,071 compared to a business class at $7,050. Recently, United Airlines has introduced a new class of service…
Read More

Global capital flows of Commercial Real Estate investments by Joshua Lee

Global capital flows of Commercial Real Estate investments: In the first half of 2018, global Commercial Real Estate (CRE) transaction volume increased 13 percent year over year (YOY) to USD$341 billion. The Americas’ volume climbed 9 percent YOY to USD$132 billion with the United States making up the majority of the growth with a volume…
Read More

Deutsche Bank’s woes continue by Luke Rochussen

On Wednesday, shares in Deutsche Bank fell to a new record low as the criminal investigation into the suspected money laundering activities of the bank’s wealth management unit continued. Then, on Thursday, the share price dropped even further following revelations that Deutsche Bank may have processed an additional €31bn of questionable funds in the Danske…
Read More

Apple and Market Saturation: Do they go hand in hand? By Prince Soni

Apple, being one of the most recognised companies worldwide, doesn’t need an introduction. The tech giant revolutionised the smartphone industry with the launch of their primary product, the iPhone. It was a phone no one had ever seen before. Alongside the iPhone, their other product lines such as the iPad, iMac, MacBook, iPod etc have…
Read More

A decade of recovery for private equity by Justin Knight

In essence: private equity (PE) refers to ownership of a company that is not publicly traded. However, since the boom of transactions funded by significant proportions of debt during the early 1980s, the term has come to describe a firm which pursues this particular type of investment strategy. A Leveraged buyout (LBO) is a type…
Read More

The Modernisation of Saudi Arabia’s Economy. By Kusum Sull

Saudi Arabia’s competitive economic edge for the last several decades has undoubtedly been due to its vast oil reserves. However, as major economies continue to shift their focus towards more sustainable commodities, Saudi Arabia has recognised the need to modernise their own economy rightly so. Crown Prince Mohammad Bin Salman’s reforms to progress the Saudi…
Read More

Can China’s Agriculture Ministry cull pigs fast enough? By Azman Rahman

‘African Swine Fever’ is a highly contagious viral disease which in its most virulent is almost 100 percent lethal to pigs and wild boars. There is currently no vaccine and the disease causes death in an average of 2-10 days through the hemorrhage of the animal’s skin and internal organs. Gruesomeness aside, we can find…
Read More

Genentech acquires Jecure Therapeutics by Malaviga Gopalakrishnan

Genentech (a subsidiary of Roche), a research-based biotechnological company, has acquired Jecure Therapeutics. Jecure specialised in drug discovery programs targeting inflammatory disorders, with a significant development in the preclinical portfolio of NLRP3 inhibitors to fight these disorders. No financial terms were disclosed, but a Genentech spokesman said it was an all-cash deal. Due to this…
Read More

AbbVie’s FDA Drug Approval – Beat and Raise Quarter by Estia Ryan

AbbVie was the strongest performer in the S&P this week, despite the recent downwards trend across market. The FDA approved Acute Myeloid Leukemia (AML) following two recent trials. AbbVie has been working with Roche on this project via Roche’s subsidiary Genentech. Share price rose for AbbVie rose to $94.27 from the initial $90.26 on Friday.…
Read More